Combination treatment for muscle-invasive bladder cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of two drugs—vedisertib (RC48) and toripalimab—for people with bladder cancer that has invaded the muscle but hasn't spread. The goal is to preserve the bladder while treating the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your bladder cancer is muscle-invasive (stage T2 to T4a) and has not spread to lymph nodes or other organs.
- Your tumor tests positive for HER2 protein (IHC 1+, 2+, or 3+).
- You have not had prior systemic treatment for this cancer.
- You are in generally good health (able to care for yourself, no major organ problems).
- You can provide a tumor sample and agree to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of probiotics, targeted therapy (RC48-ADC), and immunotherapy (Toripalimab) to treat muscle-invasive bladder cancer while preserving the bladder. The goal is to see if this combination can shrink or eliminate the cancer without needing bladder removal.
This trial tests a combination of two drugs (eribulin and toripalimab) given before surgery to remove bladder cancer. The goal is to shrink the tumor and improve outcomes for people with advanced or high-risk bladder cancer.
This trial tests combining two newer drugs (zanidatamab and tislelizumab) with standard chemotherapy before bladder surgery. The goal is to shrink the tumor so the bladder can be saved instead of removed.
This study tests a combination of two chemotherapy drugs and an immunotherapy drug given before and after surgery to remove the bladder. It aims to see if this treatment is safe and well-tolerated in patients with muscle-invasive bladder cancer.
This trial tests a combination of two medications, disitamab vedotin and toripalimab, to treat bladder cancer that has grown into the muscle layer of the bladder. The goal is to see if this treatment can save the bladder while effectively fighting the cancer.
This study tests a combination of two drugs (toripalimab and RC48-ADC) plus radiation therapy to treat bladder cancer while keeping the bladder intact. It aims to see if this approach can control the cancer without needing to remove the bladder.
Hear when a new Muscle Invasive Bladder Cancer (MIBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.